Conduct of Research and Development. As of the Effective Date, ADT has conducted all Research and Development of Compounds and Products in accordance with all Applicable Law.
Conduct of Research and Development. The parties will conduct their respective Research and Development activities under the Annual Research Plan in good 5. scientific manner and in compliance with all applicable governmental, regulatory and legal requirements. Neurocrine and Rigel will each use their good faith scientific and business judgment to allocate sufficient time, effort, equipment and facilities to. the Collaboration to achieve the objectives of the Collaboration consistent with the terms of this Agreement and the recommendations of the Steering Committee, as provided in Section 3 below.
Conduct of Research and Development. PROGRAM During the Research Term, CPG shall:
Conduct of Research and Development. RiboGene and HPI shall work diligently and use reasonable good faith efforts to identify and develop Joint Compounds and to commercialize Products pursuant to the following restrictions:
Conduct of Research and Development. 4.1. During the 12 month period commencing on the January 1, 1998, each of Elan and Endorex shall undertake to perform research and development related to the commercialisation of Products in an amount of approximately $1.5 million each, as stated in the Business Plan, in furtherance of the development and cultivation of the Program Technology. Subsequent to December 31, 1998, Elan and Endorex shall fund research and development work in accordance with their respective ownership interest in the Company. The cost of such development work shall be [****].
Conduct of Research and Development. Cell Genesys will work, at its own cost, diligently and use commercially reasonable and good faith efforts, consistent with prudent business judgment and consistent with pharmaceutical and biotechnology industry standards to implement the PDP, with qualified, experienced scientists, and in material compliance with the requirements of applicable laws and regulations in an effort to achieve its objectives efficiently and expeditiously. Cell Genesys shall maintain adequate laboratories, offices and other facilities to carry out the activities to be performed pursuant to the PDP. In conformity with standard pharmaceutical and biotechnology industry practices, the requirement of regulatory authorities and the terms and conditions of this Option Agreement, Cell Genesys shall prepare and maintain, or shall cause to be prepared and maintained, complete and accurate written records, accounts, notes, reports and raw data with respect to activities conducted pursuant to the PDP and, upon Novartis' written request, shall make legible copies of the aforesaid available to Novartis. Novartis shall have the right to freely use such primary data for archiving and regulatory purposes. Upon reasonable advance notice, both Novartis and Cell Genesys agree to make its employees and non-employee consultants reasonably available at their places of employment to consult with the other party on issues arising during the implementation of the PDP and in connection with any request from any regulatory agency, including, without limitation, regulatory, scientific, technical and clinical testing issues. Cell Genesys shall keep Novartis reasonably informed as to all relevant discoveries and technical developments (including any inventions) made under the PDP. Cell Genesys shall prepare and distribute to Novartis a reasonably detailed written summary report relating to progress regarding the PDP on an annual basis. [*] Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
Conduct of Research and Development. Junshi and its Affiliates have conducted all Development of Licensed Antibody and Licensed Products for the Coherus Territory in accordance with all applicable law.
Conduct of Research and Development. 3.1 The Parties will conduct the research and development described in the Research Plan and Development Plan, including the Sirna-027 Clinical Development Plan, and as set forth in this Section 3 below. The JSC may at any time amend in writing a plan, provided, that no such amendment may impose on Sirna any obligation or liability except as specifically set forth in this Agreement, Research Plan, and/or Development Plan, in effect as of the Effective Date, without Sirna’s consent. Allergan and Sirna will each use Scientifically Reasonable and Diligent Efforts to research, develop and commercialize Licensed Products in the Field, in the manner set forth (or to be set forth) in the Research Plan and/or Development Plan, subject to the provisions of Sections 3.6 and 3.13. As to Sirna 027
Conduct of Research and Development. [***], Exicure has conducted all Research and Development of SNAs in accordance with all Applicable Law.
Conduct of Research and Development. As of the Effective Date, CK has conducted research and development of Compounds in accordance with all applicable Law.
